At the news
? NEUTRALIMPACT 3/10 COURT-RULING filed Nov 12, 2026 at 19:00 ET
A federal magistrate judge recommended granting summary judgment on liability to Novo Nordisk against MD Exam LLC for trademark infringement, false advertising, and unfair competition related to MD Exam's unauthorized use of the Ozempic and Wegovy marks to sell compounded semaglutide. The ruling is on liability only; remedies (disgorgement, corrective advertising, injunctive relief) will be determined in further proceedings.
- Novo Nordisk granted summary judgment on liability for all five counts (trademark infringement, unfair competition, false advertising, Florida common law unfair competition, FDUTPA).
- MD Exam used Ozempic and Wegovy marks to advertise compounded semaglutide products without authorization.
- Survey evidence showed 67.4% to 82.6% of consumers were confused into believing MD Exam's products were Ozempic or equivalent.
- Remedies (disgorgement, corrective advertising costs, injunctive relief) reserved for further proceedings.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access